

Wakelee, Heather**Institution/Organization**

Stanford University and Stanford Cancer Institute

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

HW

Disclosure of Potential Conflicts

HW

COI Disclosure**Disclosures**

AstraZeneca: Advisory board, Institutional, Personal

Janssen Advisory: board Personal

Daiichi Sankyo: Advisory board Personal

Blueprint: Advisory board Personal

Mirati: Advisory role Personal

Helsinn: Advisory role Personal

Fishawack: Facilitate LTD Ongoing series of lectures Personal

Medscape AND Research to Practice AND Curio Science: Multiple CME events Personal

MJH holdings (PER): Multiple CME events/conferences Personal

UpToDate: Royalty payments, Personal

Axis Medical Education and Nexus Oncology: CME events, Personal

ACEA Biosciences: Local PI on trial Institutional

Arrys Therapeutics: Local PI of trial Institutional

BMS (and former Celgene): Local PI of trial and coordinating PI of IIT for former Celgene Institutional

Clovis Oncology: Local PI of trial Institutional

Genentech/Roche: Local PI of trial and Steering Committee Member Institutional

Merck: Local PI of trial and Steering Committee Member Institutional

Novartis: Local PI Institutional

Xcovery: Local PI of trial and Steering Committee Member Institutional

Seagen: Local PI of trial Institutional

COI Disclosure Certification

HW

Confidentiality Agreement

HW

Standards of Conduct Agreement

HW

IASLC's Tax-Exempt Status

HW

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Mitsudomi, Tetsuya**Institution/Organization**

Kindai University Faculty of Medicine

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

TM

Disclosure of Potential Conflicts

TM

COI Disclosure**Disclosures**

AstraZeneca: advisory role, speaker fee Institutional, Personal

MSD: advisor role, speaker fee Institutional, Personal

Novartis: advisor role, speaker fee Personal

MSD: advisor role, speaker fee Institutional, Personal

Bristol Myers Squibb: advisor role, speaker fee Personal

Ono: advisor role, speaker fee Personal

Pfizer: advisor role, speaker fee Personal

Boehringer Ingelheim: advisor role, speaker fee Institutional , Personal

Eli-Lilly: Speaker fee Personal

Chugai: advisor role, speaker fee, Institutional , Personal

Janssen: advisor Personal

Amgen: advisor role Personal

Daiichi-Sankyo: advisory role Personal

COI Disclosure Certification

TM

Confidentiality Agreement

TM

Standards of Conduct Agreement

TM

IASLC's Tax-Exempt Status

TM

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Amounts listed for institutions includes clinical trials and research grants.

Amounts listed for personal are mostly honoraria for the invited speeches, advisory role, and/or manuscript preparation

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Outside organizations:

- emeritus member, Japan Lung Cancer Society
- emeritus member, Japanese Association of Chest Surgery
- emeritus member, Japanese Society of Medical Oncology
- council member, Japan Surgical Society

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Van Schil, Paul**Institution/Organization**

Antwerp University Hospital

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

PVS

Disclosure of Potential Conflicts

PVS

COI Disclosure**Disclosure List****Disclosures**

AstraZeneca: External expert, Institutional

MSD: External expert, Institutional

National Cancer Institute (France): External expert, Institutional

BACTS (Belgian Association for Cardio-Thoracic Surgery): Treasurer - board member, Institutional

COI Disclosure Certification

PVS

Confidentiality Agreement

PVS

Standards of Conduct Agreement

PVS

IASLC's Tax-Exempt Status

PVS

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Bezjak, Andrea**Institution/Organization**

Princess Margaret Cancer Center

Primary Specialty

Radiation Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

AB

Disclosure of Potential Conflicts

AB

COI Disclosure**Disclosures**

Princess Margaret Cancer Center: employment, Personal

University of Toronto: academic appointment, Personal

Astra Zeneca: Advisory Board, Personal

COI Disclosure Certification

AB

Confidentiality Agreement

AB

Standards of Conduct Agreement

AB

IASLC's Tax-Exempt Status

AB

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

I have no clinical trials with RT companies.

Thunnissen, Erik

Institution/Organization

VU University Medical Center

Primary Specialty

Pathology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

yes, et

Disclosure of Potential Conflicts

et

COI Disclosure

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

et

Confidentiality Agreement

et

Standards of Conduct Agreement

difficult to read, et

IASLC's Tax-Exempt Status

et

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Aerts, Joachim

Institution/Organization

Erasmus University Medical Center

Primary Specialty

Pulmonary Medicine

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

ja

Disclosure of Potential Conflicts

ja

COI Disclosure

Disclosures

MSD, BMS, Boehringer Ingelheim, Roche, Eli-Lilly: Consultancy and speaker

BIOCAD: speaker, consultant, DSMB member

Amphera: stock owner and scientific advisor

COI Disclosure Certification

ja

Confidentiality Agreement

ja

Standards of Conduct Agreement

ja

IASLC's Tax-Exempt Status

ja

Moreira Ferreira, Carlos Gil

Institution/Organization

Instituto Oncoclinicas

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

CGF

Disclosure of Potential Conflicts

CGF

COI Disclosure

Disclosures

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

CGF

Confidentiality Agreement

CGF

Standards of Conduct Agreement

CGF

IASLC's Tax-Exempt Status

CGF

Gray, Jhanelle**Institution/Organization**

Moffitt Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

JG

Disclosure of Potential Conflicts

JG

COI Disclosure**Disclosures**

Moffitt Cancer Center: Full Member, Department Chair and Program Leader

ASCO: Committee Member and Chair Elect; Grant Reviewer

IASLC: Committee Chair

EMD Serono: Consultant/Advisor; Research Support

Loxo: Research Support

AstraZeneca: Advisory/Consultant; Research Support

BluePrint Medicine: Advisor

BMS: Consultant/Advisor

BMS: Research Support

Novartis: Research Support

Eli Lilly: Consultant/Advisor

Ludwig Institute: Research Support

Genentech: Research Support

BI: Research Support

Merck: Consultant/Advisor

Merck: Research Support

Pfizer: Research Support

Novartis: Consultant/Advisor

Inivata: Consultant/Advisor

Sanofi: Advisor

SWOG: Lung Committee member; Lung Working Group member; LUNGMAP committee member; LUNGMAP study Chair

AACR: Abstract Panel Review Member

COI Disclosure Certification

JG

Confidentiality Agreement

JG

Standards of Conduct Agreement

JG

IASLC's Tax-Exempt Status

JG

Herbst, Roy**Institution/Organization**

Yale Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

RSH

Disclosure of Potential Conflicts

RSH

COI Disclosure**Disclosures**

AstraZeneca: Pharmaceuticals Consulting, Personal

EMD Serono Inc.: Consulting, Personal

Immunocore: Consulting, Personal

Johnson and Johnson: Consulting, Personal

Merck & Company, Inc: Consulting, Personal

Mirati Therapeutics: Consulting, Personal

Novartis Oncology: Consulting, Personal

STCube Pharmaceuticals, Inc: Consulting, Personal

Xencor, Inc: Consulting, Personal

AstraZeneca: Pharmaceuticals Research (Clinical Trials), Institutional

Genentech/Roche: Research (Clinical Trials), Institutional

Merck & Company, Inc: Research (Clinical Trials), Institutional

Immunocore Holdings Limited: Board Member (non-executive/independent), Personal

to include stock options in 2021

Junshi Biosciences Co., Ltd.: Board Member (non-executive/independent), Personal

Cybrexa Therapeutics: Consulting, Personal

eFFECTOR Therapeutics, Inc.: Consulting, Personal

Eli Lilly and Company: Consulting, Personal

I-Mab Biopharma: Consulting, Personal

Next Cure: Consulting, Personal

Bolt Biotherapeutics: Consultant, Personal, 2500 options (intrinsic value as of 4/21/2021: \$0.00)

COI Disclosure Certification

RSH

Confidentiality Agreement

RSH

Standards of Conduct Agreement

RSH

IASLC's Tax-Exempt Status

RSH

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Those institutional amounts are the research study support.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Kim, Young Tae

Institution/Organization

Seoul National University

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

YTK

Disclosure of Potential Conflicts

YTK

COI Disclosure

Disclosures

Johnson and Johnson: Consult

COI Disclosure Certification

YTK

Confidentiality Agreement

YTK

Standards of Conduct Agreement

YTK

IASLC's Tax-Exempt Status

YTK

Quist, Morten

Institution/Organization

University hospital Copenhagen

Primary Specialty

Resp Therapy/Physiotherapy

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

MQ

Disclosure of Potential Conflicts

MQ

COI Disclosure

Disclosures

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

MQ

Confidentiality Agreement

MQ

Standards of Conduct Agreement

MQ

IASLC's Tax-Exempt Status

MQ

Richeimer, Kristin

Institution/Organization

IASLC

Primary Specialty

Patient Advocacy

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

KMR

Disclosure of potential Conflicts

KMR

COI Disclosure

Disclosures

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

KMR

Confidentiality Agreement

KMR

Standards of Conduct Agreement

KMR

IASLC's Tax-Exempt Status

KMR

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Sequist, Lecia

Institution/Organization

Massachusetts General Hospital

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

LS

Disclosure of Potential Conflicts

LS

COI Disclosure

Disclosures

AstraZeneca: Consulting

Janssen: Consulting

Genentech: consulting

Novartis: Clinical trial

AstraZeneca: Clinical Trial

Boehringer Ingelheim: Clinical trial

Genentech: clinical trial

COI Disclosure Certification

LS

Confidentiality Agreement

LS

Standards of Conduct Agreement

LS

IASLC's Tax-Exempt Status

LS

Tsao, Ming Sound

Institution/Organization

Princess Margaret Cancer Centre

Primary Specialty

Pathology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

MST

Disclosure of Potential Conflicts

MST

COI Disclosure

Disclosures

University Health Network, Princess Margaret Cancer Centre: Senior Scientist and Consultant Pathologist

Merck: Medical Advisory Board meeting

Bayer: PI of a multi-institutional research grant to standardize IHC and NGS testing to detect NTRK fusions in cancer (2019-2021)

Bayer: Honoraria for Advisory Board consultancy meeting and meeting speaker

AstraZeneca: Advisory Board consultancy meeting

Bristol-Myers Squibb: Advisory Board consultancy meeting honorarium

COI Disclosure Certification

MST

Confidentiality Agreement

MST

Standards of Conduct Agreement

MST

IASLC's Tax-Exempt Status

MST

Ugalde, Paula

Institution/Organization

Institut Universitaire de Cardiologie et de Pneumologie de Québec - IUCPQ

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

PU

Disclosure of Potential Conflicts

PU

COI Disclosure

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

PU

Confidentiality Agreement

PU

Standards of Conduct Agreement

PU

IASLC's Tax-Exempt Status

PU

Zhou, Caicun**Institution/Organization**

Tongji University Shanghai Pulmonary Hospital

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

ZCC

Disclosure of Potential Conflicts

ZCC

COI Disclosure**Disclosures**

Lily China: honoraria as a speaker, Personal

Sanofi: honoraria as a speaker, Personal

BI: honoraria as a speaker, Personal

Roche China: honoraria as a speaker, Personal

MSD: honoraria as a speaker, Personal

Qilu: honoraria as a speaker, Personal

Hengrui: honoraria as a speaker and Advisor, Personal

Innovent Biologics: honoraria as a speaker and advisor, Personal

C-Stone: honoraria as a speaker, Personal

LUYE Pharma: honoraria as a speaker, Personal

TopAlliance Biosciences Inc: honoraria as a speaker and Advisor, Personal

Amoy Diagnostics: honoraria as a speaker, Personal

COI Disclosure Certification

ZCC

Confidentiality Agreement

ZCC

Standards of Conduct Agreement

ZCC

IASLC's Tax-Exempt Status

ZCC

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?